Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|38|6|316-317

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.38, Iss.6, 2015-06, pp. : 316-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Afatinib with Concurrent Radiotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 37, Iss. 5, 2014-04 ,pp. : 262-265

Karger

Access to resources Recommend Favorite

Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3761-3768

John Wiley & Sons Inc

Access to resources Recommend Favorite

Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer

By Bordoni Rodolfo E  

Therapy, Vol. 8, Iss. 1, 2011-01 ,pp. : 15-22

Future Medicine

Access to resources Recommend Favorite

Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy

By  

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-01 ,pp. : 15-20

Karger

Access to resources Recommend Favorite

EGFR-TKI Treatment and Surgical Resection for Oligometastatic NSCLC?

By  

Oncology Research and Treatment, Vol. 32, Iss. 11, 2009-10 ,pp. : 627-628

Karger

Access to resources Recommend Favorite